Navigation Links
Telik Regains Compliance With Minimum Bid Price Requirement
Date:4/17/2012

PALO ALTO, Calif., April 17, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced that it has received from The Nasdaq Stock Market notification that Telik has regained compliance with the minimum bid price rule for continued listing on The Nasdaq Capital Market because the bid price of Telik's common stock has closed at $1.00 per share or greater for at least 10 consecutive business days.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic disorders including myelodysplastic syndrome; followed by Telcyta®, a cancer activated drug for the treatment of a variety of cancers.  Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.  Additional information is available at www.telik.com.

TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Telik Announces Fourth Quarter and 2011 Year End Financial Results and 2012 Financial Guidance
2. Telik Announces Presentation and Webcast at 14th Annual BIO CEO & Investor Conference
3. Telik Announces Telintra Clinical Presentations at the Annual Meeting of the American Society of Hematology
4. Telik Announces Third Quarter 2011 Financial Results
5. Telik Announces Publication of a Report of Complete Response of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment with Telintra®
6. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
7. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
8. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
9. Telik Announces First Quarter 2011 Financial Results
10. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
11. Telik Announces Presentation and Webcast at 10th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... PurhealthRX , a leading Health and Nutrition Company, ... Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market by ... be easily incorporated into liquid products, while reducing costs to end users. , The ...
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):